{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:49:26Z","timestamp":1790426966860,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TI 323\/4-1"],"award-info":[{"award-number":["TI 323\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12985-017-0779-4","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T08:26:18Z","timestamp":1496910378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure"],"prefix":"10.1186","volume":"14","author":[{"given":"Andreas","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Filke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Obermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"H\u00e4ussinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans H.","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"779_CR1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address, e.e.e., EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153\u201394. PMID: 27667367.","DOI":"10.1016\/j.jhep.2016.09.001"},{"issue":"4","key":"779_CR2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127\u201335.","journal-title":"Hepatology"},{"issue":"5","key":"779_CR3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrgastro.2015.53","volume":"12","author":"P Ferenci","year":"2015","unstructured":"Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12(5):284\u201392.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"779_CR4","doi-asserted-by":"crossref","unstructured":"Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70-86. PMID: 27080301.","DOI":"10.1053\/j.gastro.2016.04.003"},{"issue":"2","key":"779_CR5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486\u2013504.","journal-title":"J Hepatol"},{"issue":"1","key":"779_CR6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","volume":"57","author":"D Hernandez","year":"2013","unstructured":"Hernandez D, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57(1):13\u20138.","journal-title":"J Clin Virol"},{"issue":"1","key":"779_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","volume":"61","author":"EF Donaldson","year":"2015","unstructured":"Donaldson EF, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61(1):56\u201365.","journal-title":"Hepatology"},{"issue":"11","key":"779_CR8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/jvh.12405","volume":"22","author":"C Hedskog","year":"2015","unstructured":"Hedskog C, et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat. 2015;22(11):871\u201381.","journal-title":"J Viral Hepat"},{"issue":"12","key":"779_CR9","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","volume":"59","author":"ES Svarovskaia","year":"2014","unstructured":"Svarovskaia ES, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59(12):1666\u201374.","journal-title":"Clin Infect Dis"},{"key":"779_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcv.2015.07.008","volume":"70","author":"A Walker","year":"2015","unstructured":"Walker A, et al. Natural prevalence of resistance-associated variants in hepatitis C virus NS5A in genotype 3a-infected people who inject drugs in Germany. J Clin Virol. 2015;70:43\u20135.","journal-title":"J Clin Virol"},{"issue":"5","key":"779_CR11","doi-asserted-by":"crossref","first-page":"e0155869","DOI":"10.1371\/journal.pone.0155869","volume":"11","author":"P Kalaghatgi","year":"2016","unstructured":"Kalaghatgi P, et al. Geno2pheno[HCV] - a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One. 2016;11(5):e0155869.","journal-title":"PLoS One"},{"issue":"6","key":"779_CR12","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28782","volume":"64","author":"EB Tapper","year":"2016","unstructured":"Tapper EB, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893\u20139.","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"779_CR13","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S0168-8278(15)30073-8","volume":"62","author":"H Dvory-Sobol","year":"2015","unstructured":"Dvory-Sobol H, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol. 2015;62(Suppl 2):S221.","journal-title":"J Hepatol"},{"key":"779_CR14","doi-asserted-by":"crossref","unstructured":"Krishnan P, et al. O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir\/r-, ombitasvir- and dasabuvir-based regimens. J Hepatol. 2015;62(Suppl 2):S220.","DOI":"10.1016\/S0168-8278(15)30071-4"},{"issue":"3","key":"779_CR15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","volume":"58","author":"F McPhee","year":"2013","unstructured":"McPhee F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013;58(3):902\u201311.","journal-title":"Hepatology"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-017-0779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T08:26:31Z","timestamp":1496910391000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-017-0779-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1186\/s12985-017-0779-4","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]},"article-number":"106"}}